Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO3300074 for alpha-1-antitrypsin deficiency emphysema
2004-001688-23Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of palovarotene in alpha-1 antitrypsin deficiency (AATD) and emphysema (2 arms), sponsored by Roche. Primary endpoint: Change from baseline in 15th percentile lung density adjusted for lung volume at 12 months. Started Oct 2004; status: completed.
02
Drugs
palovarotene
03
Conditions
alpha-1 antitrypsin deficiency (AATD)emphysema
Beyond the preview
Go deeper on 2004-001688-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001688-23.